MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-06-2026
Mettler-Toledo International Retained Earnings 2011-2026 | MTD
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Mettler-Toledo International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.24 B | 8.37 B | 7.51 B | 6.73 B | 5.86 B | 5.1 B | 4.5 B | 3.94 B | 3.43 B | 3.07 B | 2.69 B | 2.36 B | 2.04 B | 1.75 B | 1.48 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.24 B | 1.48 B | 4.54 B |
Quarterly Retained Earnings Mettler-Toledo International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.95 B | 8.74 B | 8.53 B | 8.37 B | 8.12 B | 7.91 B | - | 7.51 B | 7.33 B | 7.13 B | 6.91 B | 6.73 B | 6.46 B | - | 6.03 B | 5.86 B | 5.63 B | 5.43 B | 5.24 B | 5.1 B | 5.1 B | 5.1 B | 5.1 B | 4.5 B | 4.5 B | 4.5 B | 4.5 B | 3.94 B | 3.94 B | 3.94 B | 3.94 B | 3.43 B | 3.43 B | 3.43 B | 3.16 B | 3.07 B | 3.07 B | 3.07 B | 3.07 B | 2.69 B | 2.69 B | 2.69 B | 2.69 B | 2.36 B | 2.36 B | 2.36 B | 2.36 B | 2.04 B | 2.04 B | 2.04 B | 2.04 B | 1.75 B | 1.75 B | 1.75 B | 1.75 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.95 B | 1.48 B | 4.25 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Fulgent Genetics
FLGT
|
590 M | $ 15.96 | 5.63 % | $ 483 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 16.76 | 1.09 % | $ 177 M |  China |
 |
Castle Biosciences
CSTL
|
-224 M | $ 19.83 | 3.07 % | $ 575 M | USA |
 |
Agilent Technologies
A
|
348 M | $ 115.62 | -2.55 % | $ 35.1 B | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
-735 M | $ 21.82 | 1.77 % | $ 1.16 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Lantheus Holdings
LNTH
|
680 M | $ 93.06 | 2.26 % | $ 6.28 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 424.0 | -1.1 % | $ 12.2 B | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 2.53 | 31.09 % | $ 3.37 M | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.29 | 4.89 % | $ 397 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 8.96 | -1.21 % | $ 1.15 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 18.75 | 0.11 % | $ 420 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Natera
NTRA
|
-1.94 B | $ 194.24 | -11.64 % | $ 19.1 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 177.62 | -2.23 % | $ 8.8 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Personalis
PSNL
|
-631 M | $ 5.98 | -0.17 % | $ 534 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 95.7 | 3.73 % | $ 12 B | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 5.03 | -6.16 % | $ 210 M | USA |
 |
Soleno Therapeutics
SLNO
|
-431 M | $ 52.95 | - | $ 2.69 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 124.49 | -0.41 % | $ 10.3 B |  Irlanda |
 |
Illumina
ILMN
|
-1.24 B | $ 141.88 | 2.29 % | $ 22.6 B | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.95 | -2.5 % | $ 8.63 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Trinity Biotech plc
TRIB
|
-79.1 M | $ 0.61 | 2.52 % | $ 219 M | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 56.85 | -2.89 % | $ 3.4 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.15 | -2.05 % | $ 4.94 M | USA |
 |
Thermo Fisher Scientific
TMO
|
59.2 B | $ 465.0 | -1.99 % | $ 175 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 254.12 | -1.52 % | $ 21.1 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 131.06 | 0.27 % | $ 6.13 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Waters Corporation
WAT
|
10.4 B | $ 355.13 | 1.32 % | $ 21.1 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.05 | -2.16 % | $ 1.96 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 187.39 | -1.82 % | $ 20.8 B | USA |